Abstract
Asthma shows heterogeneity in the cellular sources of inflammation and response to therapy. Although glucocorticoids (GC) are very effective for the treatment of most patients with asthma, an important subgroup of patients fails to show clinical improvement. GC resistance (GC-R) could result from either inherited or acquired variation in GC sensitivity. Diverse cells, such as T helper (Th)1 cells, Th2 cells, and Th17 cells, and innate immunity associated pathways are involved in GC-R asthma. The GC receptor (GR) plays a central role in GC sensitivity. Recent molecular biological studies have revealed the involvement of protein kinase signaling to GR, GR phosphorylation, interactions of GR with excessive activation of transcription factors, and impaired histone deacetylase (HDAC). Long-acting β(2)-adrenoceptor agonists (LABAs) may improve the clinical efficacy of GCs by enhancing GR function. Inhibitors of kinase pathways, such as p38 mitogen-activated protein kinase (MAPK) inhibitors and phosphoinositide-3-kinase (PI3K)δ inhibitors, are candidates for new therapeutic agents for GC-R asthma.
Keywords: Glucocorticoid (GC), glucocorticoid-resistant (GC-R) asthma, glucocorticoid receptor (GR), histone deacetylase (HDAC), long-acting β(2)-adrenoceptor agonists (LABAs), mitogen-activated protein kinase (MAPK), phosphoinositide-3- kinase (PI3K).
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Inflammatory Cellular Phenotypes and Molecular Mechanisms of Glucocorticoid Resistance in Patients with Bronchial Asthma
Volume: 12 Issue: 3
Author(s): Yasuhiro Matsumura
Affiliation:
Keywords: Glucocorticoid (GC), glucocorticoid-resistant (GC-R) asthma, glucocorticoid receptor (GR), histone deacetylase (HDAC), long-acting β(2)-adrenoceptor agonists (LABAs), mitogen-activated protein kinase (MAPK), phosphoinositide-3- kinase (PI3K).
Abstract: Asthma shows heterogeneity in the cellular sources of inflammation and response to therapy. Although glucocorticoids (GC) are very effective for the treatment of most patients with asthma, an important subgroup of patients fails to show clinical improvement. GC resistance (GC-R) could result from either inherited or acquired variation in GC sensitivity. Diverse cells, such as T helper (Th)1 cells, Th2 cells, and Th17 cells, and innate immunity associated pathways are involved in GC-R asthma. The GC receptor (GR) plays a central role in GC sensitivity. Recent molecular biological studies have revealed the involvement of protein kinase signaling to GR, GR phosphorylation, interactions of GR with excessive activation of transcription factors, and impaired histone deacetylase (HDAC). Long-acting β(2)-adrenoceptor agonists (LABAs) may improve the clinical efficacy of GCs by enhancing GR function. Inhibitors of kinase pathways, such as p38 mitogen-activated protein kinase (MAPK) inhibitors and phosphoinositide-3-kinase (PI3K)δ inhibitors, are candidates for new therapeutic agents for GC-R asthma.
Export Options
About this article
Cite this article as:
Matsumura Yasuhiro, Inflammatory Cellular Phenotypes and Molecular Mechanisms of Glucocorticoid Resistance in Patients with Bronchial Asthma, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (3) . https://dx.doi.org/10.2174/18715230113129990010
DOI https://dx.doi.org/10.2174/18715230113129990010 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial:Hot Topic: [Exploiting Multivalency in Drug Design(Executive Editor: Diego Munoz-Torrero)]
Current Pharmaceutical Design Review in Pharmacokinetic Models on Corticosteroids
Mini-Reviews in Medicinal Chemistry Effect of Herbal Aphrodisiac, <i>Dioscorea Bulbifera</i> on Sperm Parameters, Serum Hormonal Levels and Testicular Histology of Wistar Rats
Current Traditional Medicine Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry The Role of Structural Cells on Airway Remodeling and Their Response to Asthma Medication
Current Respiratory Medicine Reviews Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Adenovirus and Post-Infectious Bronchiolitis Obliterans in Children
Current Pediatric Reviews Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Neutrophilic Asthma and Potentially Related Target Therapies
Current Drug Targets Chronopharmaceutics: A Promising Drug Delivery Finding of the Last Two Decades
Recent Patents on Drug Delivery & Formulation Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Adverse Reactions to Iodinated Contrast Media Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Inflammation & Allergy - Drug Targets (Discontinued) Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Opioid-induced Respiratory Depression
Current Pharmaceutical Design Respiratory Syncytial Virus Bronchiolitis and Asthma – Insights from Recent Studies and Implications for Therapy
Inflammation & Allergy - Drug Targets (Discontinued) The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets